A decentralized clinical trial (DCT) platform is the technology stack that coordinates on-site and remote activity, connecting trial partners, vendors, and tools rather than replacing any of them. For trials with ophthalmic endpoints, that platform can manage data and scheduling, but it can't substitute for the assessment itself: BCVA, OCT, IOP, and other ocular measures require calibrated equipment and certified operators, which means decentralization has to be built as a hybrid execution model from day one, not layered on afterward.
More sponsors are choosing DCTs over fully traditional trials, often to solve for low enrollment and poor retention. Patient-centric trial design is one of the more effective retention strategies available, since it enables participation from people across a wider range of backgrounds, which in turn improves the generalizability of trial results to real-world settings. If you're planning a decentralized trial that includes ophthalmic endpoints, that flexibility only pays off if the ophthalmic assessment piece is designed correctly from the start.
In a decentralized trial, the technology stack enables execution without relying on a fully on-site model, making it easier to coordinate on-site and decentralized activities while providing sponsors with oversight and reporting across sites, providers, and vendors. A DCT platform isn't a single, standalone solution. It's a connective layer between trial partners and the various technology tools a study actually runs on. As trials shift from purely site-based models toward hybrid and decentralized options, that connective layer provides the flexibility participants need, alongside the ongoing support required for high-quality data collection.
Ophthalmic endpoints are particularly difficult to measure in a decentralized trial. Capturing this data requires highly sensitive equipment operated by trained technicians, in an environment that must be closely monitored to maintain standardized data collection throughout the study.
Other types of clinical studies can often run on questionnaires or wearable-collected vitals alone. Most ophthalmic endpoints can't be assessed in a fully virtual or software-based trial. This is where many DCT strategies fail: the design assumes that digital convenience can replace controlled clinical conditions. When endpoint integrity depends on calibrated equipment and certified operators, decentralization has to be built on a hybrid execution model from the first phase of planning. Skip that step, and the data collected may not meet the standards required for accurate results and FDA approval, which can put the entire trial at risk before it even starts.
Technology is the backbone of decentralized and hybrid trials, but its role is data management, not data collection for endpoints requiring in-person assessment. A specialized technology ecosystem centralizes data across sites and gathers real-time information, while enabling more efficient scheduling that helps reduce missed follow-ups. It also supports remote monitoring, which improves participant engagement and adherence to trial requirements, and generates the audit trails sponsors rely on during inspections. Without those audit trails, demonstrating that a trial actually met regulatory requirements gets significantly harder.
One of the persistent challenges in hybrid or decentralized trials is gathering all acquired data and cleanly integrating it into CRO and sponsor workflows. The right technology streamlines that process without forcing an overhaul of existing workflows.
Most ophthalmic assessments need to be performed by certified clinicians using clinical-grade, calibrated equipment, which isn't feasible in a fully virtual trial without compromising data integrity. These assessments also depend on a controlled environment: lighting, participant positioning, and several other factors can all influence results, and untrained participants can't be expected to manage those conditions on their own. Asking them to try adds a burden that can push participants to abandon the trial altogether.
Mobile and on-site delivery models solve this without adding that burden, since participants don't have to travel to a central site for every scheduled check-in. That still delivers the reliable data capture needed to meet regulatory requirements, without sacrificing enrollment. Extending participation to people who can't manage frequent travel widens the pool to include participants from a broader range of socioeconomic backgrounds, which matters directly for how well the results generalize. Traditional trial designs often place an undue burden on underserved and marginalized populations, since inability to take time off work and transportation access shut many people out of studies before they ever have a chance to enroll.
Specialized providers focused on ophthalmic assessments can support both hybrid and traditional trials, working alongside the platforms that manage trial data rather than in place of them. A well-integrated model gives sponsors confidence that equipment is calibrated to a consistent standard and that trained, certified technicians are performing accurate assessments. The technology and the clinical execution don't replace each other; they work together to produce reliable results and a better participant experience.
Coordination between ophthalmic services and technology matters because it determines how quickly assessment data reaches the trial's centralized system for review. Poor coordination introduces delays, skewed results, and the kind of gaps that draw regulatory board questions. With a provider that supports integrated workflows, ophthalmic data flows into central systems for timely review and analysis instead of sitting in a separate silo. Point-of-need ophthalmic clinical trial solutions are built specifically to close that gap.
The first question is whether a decentralized model is appropriate for the hybrid, in-person assessments the protocol requires. Difficulty recruiting or retaining participants is one of the more common reasons sponsors need clinical trial rescue services, making getting the design right up front worth the extra planning time.
A patient-centric, balanced trial design matters most here: in addition to asking participants to travel to a primary site when necessary, sponsors need to meet them halfway with mobile data capture. Data quality has to come first, but adverse event monitoring and reporting still need strong protocols across every site in the trial. Regulatory alignment deserves early attention too. Engaging the FDA and other bodies early on validation requirements for remote digital health technologies protects the trial from using unapproved tools that could block eventual approval.
Participant privacy and data protection round out the list. Every technology used in a hybrid trial needs end-to-end encryption, and informed consent processes need the same rigor in a decentralized design as they would on-site. Ultimately, sponsors need to weigh whether a decentralized approach protects clinical data while remaining convenient enough to out-recruit a traditional trial design, and for many ophthalmic trials, that balance clearly tips in favor of decentralization done right.
Ophthalmic endpoints are notoriously difficult to incorporate into fully remote trials, which is why decentralized platforms have to balance oversight of mobile assessment sites with at-home monitoring rather than choosing one over the other. Decentralization only works in this context when clinical services and technology stay aligned, and a balanced trial design that blends participant flexibility with controlled assessment conditions is what makes that alignment possible.
Request a virtual clinical trial tour to see how 20/20 Onsite combines specialized point-of-need care with centralized oversight, or schedule a consultation with our clinical trial ophthalmic services team to protect ocular endpoints in your next decentralized or hybrid trial.
What is a decentralized clinical trial platform? It's the technology stack that coordinates on-site and remote trial activity, connecting sponsors, sites, vendors, and tools rather than acting as a single standalone system. It provides oversight, reporting, and data centralization across every location a trial runs.
Can ophthalmic endpoints be captured in a fully virtual decentralized trial? Rarely to the standard sponsors need. Most ophthalmic endpoints require calibrated, clinical-grade equipment operated by certified technicians in a controlled environment, which a fully virtual or software-only model can't replicate without compromising data integrity.
Why does decentralization need to be hybrid for trials with ocular endpoints? Because endpoint integrity depends on equipment and operator standards that only a trained clinician using calibrated instruments can meet. Building the trial as hybrid from the first phase of planning avoids collecting data that later falls short of FDA approval standards.
How does decentralization improve participant diversity in ophthalmic trials? By removing the requirement to travel to a central site for every visit, decentralized and hybrid models extend participation to people who can't manage frequent travel, including participants from a wider range of socioeconomic backgrounds. That broader participant base also improves how well trial results generalize to real-world settings.
What should sponsors evaluate before choosing a decentralized model for ophthalmic endpoints? Whether the model can support the hybrid, in-person assessments the protocol requires, how adverse events will be monitored and reported across sites, how early regulatory alignment on digital health technologies will be pursued, and whether data protection and informed consent processes meet the same standard as an on-site trial.
How does 20/20 Onsite support decentralized trials with ophthalmic endpoints? 20/20 Onsite provides point-of-need ophthalmic clinical trial solutions that integrate directly with a sponsor's existing decentralized trial platform, delivering calibrated equipment and certified technicians so assessment data flows into centralized systems for timely review.
What happens if ophthalmic assessment data isn't well integrated into a trial's technology platform? Poor integration delays data entry into the centralized system, increases the risk of skewed results, and can draw regulatory board questions during review. A provider that supports integrated workflows keeps ophthalmic data moving into central systems without those gaps.